Three MNCs Denied India Price Increases For Eye, Diabetes Products
This article was originally published in PharmAsia News
Executive Summary
Allergan, Novartis and Sanofi have been denied India permission to increase the prices of certain imported drugs on grounds they failed to persuade the National Pharmaceutical Pricing Authority they were justified.